

IN THE SPECIFICATION:

Please amend the specification as follows:

After the title and before the first paragraph please insert the following new paragraph:

This application is the National Stage of International Application No. PCT/JP03/02361 filed March 7, 2003.

At page 6 of the originally-filed specification after the second complete paragraph (just before the Examples) please insert the following:

Brief Description of the Drawings

Fig. 1 is an antibody blot (Blot-Ab) which demonstrates that tyrosine phosphorylation of EGFR and Shc occur after stimulation with GPCR ligands and are downregulated by BB94 and AG1478.

Fig. 2 is an antibody blot (Blot-Ab) which demonstrates that phosphorylation of mitogen activated protein kinase after stimulation with GPCR ligands is downregulated by BB94 and AG1478.

Fig. 3 contains data from a thymidine incorporation assay which shows that LPA-induced proliferation of lung cancer cell line H292 can be inhibited by BB94 and AG1478.

Fig. 4 contains data from an apoptosis assay which shows that LPA-induced anti-apoptotic effects in the bladder cancer cell line TccSup can be inhibited by BB94 and AG1478.

Fig. 5 contains data from a migration assay which shows that LPA-induced migration in the kidney cancer cell line A498 can be inhibited by BB94 and AG1478.

Fig. 6 contains data from a study on LPA-induced wound closure in the kidney carcinoma cell

line ACHN and the inhibitory effects of BB94 and AG1478.

Fig. 7 contains data from an invasion assay which shows that LPA-induced invasion in the kidney carcinoma cell line CaKi2 can be diminished by BB94 and AG1478.